|
Oxybutynin
Should certain beverages, foods and other products be avoided when i take generic oxybutynin.
Propiverine hydrochloride Detrunorm Mictonorm Germany ; Tablets containing 15mg propiverine hydrochloride Drugs for treatment of urinary incontinence BNF 7.4.2 ; The treatment of urinary incontinence, as well as urgency and frequency in unstable bladder conditions, in patients who have either idiopathic bladder instability, or neurogenic bladder detrusor hyperreflexia ; from spinal cord injuries, e.g. transverse lesion paraplegia. Adults: As a standard dose one tablet 15mg ; twice daily increased, if necessary, to three times daily. Some patients may respond to a dosage of 15mg daily. For reflex incontinence a dose of one tablet three times daily is recommended. This may be increased to four times a day if necessary and if tolerated maximum recommended daily dose ; . Elderly: No specific dose regimen is recommended. Propiverine may prove to be a useful second-line drug in patients in whom side-effects particularly dry mouth ; are troublesome while taking oxybutynin.
Accu-Check . Logic, Ascensia Contour, Ascensia Breeze Allegra-D Ioratadine D, Zyrtec D Altace . Lisinopril, Benazepril, Enalapril, Mavik, Aceon Amerge . Zomig, Relpax, Imitrex Avalide . Atacand HCT, Diovan HCT Avapro . Atacand, Diovan Azmacort . Pulmicort Benicar . Atacand, Diovan Clarinex . Loratadine, Zyrtec Covera HS Cardizem LA Cozaar . Atacand, Diovan Ditropan XL Oxybutynin, Detrol LA, Enablex Enbrel . Humira Foradil . Serevent Frova . Zomig, Relpax, Imitrex Hyzaar . Atacand HCT, Diovan HCT Levoxyl . Levothyroxine, Synthroid Lexapro . Citalopram, Paroxetine, Fluoxetine, Zoloft Lexxel . Tarka, Lotrel Lumigan . Xalatan Maxalt . Zomig, Imitrex, Relpax Nasonex . Flonase, Rhinocort Aqua Patanol . Optivar Pravachol . Iovastatin, Lipitor, Crestor Prevacid . Omeprazole, Nexium, Protonix One Touch Ultra . Ascensia Contour, Ascensia Breeze, BD Logic Sonata . Ambien, Ambien CR Travatan . Xalatan Verelan . Cardizem LA Vytorin . Iovastatin, Lipitor, Crestor Xenical . Meridia Zaditor . Optivar Zocor . Iovastatin, Lipitor, Crestor.
Regardless of higher skeletal bone mineral density, Japanese postmenopausal women who are overweight may have an increased risk of tooth loss compared with those with normal body mass index. This risk may be similar to that for underweight postmenopausal women who have lower skeletal bone mineral density. Ozybutynin for refractory hot flashes in cancer patients.
Table 1 summary of clustering test search results.
Many insurance plans encourage you to accept the generic version of a drug whenever its medically safe and prednisolone.
Se deber mejorar la coordinacin interinstitucional para: a ; Difundir las acciones que mejoren el almacenamiento de estos productos especialmente plaguicidas, como el adecuado manejo en los comercios y en los establecimientos agropecuarios, incluyendo acciones de descontaminacin frente a derrames. b ; Instruir y difundir medidas de precaucin para el transporte de estos productos, desde los comercios donde se adquieren a los establecimientos rurales. c ; Enfatizar en la bsqueda de soluciones a los problemas de eliminacin de envases y deshechos de algunos principios activos y formulaciones, especialmente de plaguicidas agrcolas y ectoparasiticidas, en conjunto con otros Ministerios involucrados, y con participacin de la industria el comercio y los usuarios. 120.
Adoption of a list of essential drugs is part of a national health policy. This implies that priority is given to achieving the widest possible coverage of the population with drugs of proven efficiency and safety, in order to meet the needs for prevention and treatment of the most prevalent disease. - Criteria for the selection of essential drugs are intended to ensure that the process of selection will be unbiased and based on the best available information and protonix, because oxybutynin cl er.
Buy generic Oxybutynin
State medical number of travel se involve advocacy worn.
There are not many well-conducted studies looking at the efficacy of antidepressant drug therapy in children and adolescents suffering from depressive disorders 19 and theo-dur.
Are specialized in metabolic disorders including obesity and the metabolic syndrome at the Graz University Hospital which is among the largest hospitals in mid Europe : lkh-graz ; as well as research laboratories focusing on human nutrition : hnmrc -graz ; , food chemistry and technology TUG ; , basic obesity research in molecular biosciences IMB, ZMF ; using transgenic animal models : gold -graz ; . 2. DIETS thematic network: the Unit has also participated in the successful creation of an ERASMUS 3 thematic network project number ; composed of 112 Faculty and Professional Associations from 30 European countries. The aims and objectives of the network are to build a network of dietetic practitioners, dietetic educators, nutritional scientists and others involved in the pursuit of nutritional health and well-being in Europe. The purpose of sharing and dissemination of key dietetic knowledge, best practice and to encourage evidence based dietetic practice is to realize the full potential of the dietitian working in Europe in the promotion of health. An important feature of the network is to commence the implementation of the European Dietetic Benchmark Statement thereby contributing to the Bologna Process. Within the Benchmark are key guidelines for mastery of dietetic practice and the Network will work towards building a set of practical dietetic competency statements which will build on best educational practice. The DIETS Network will establish a virtual network of key groups engaged in areas related to food production, clinical medicine, other healthcare practitioners and students of dietetics to share information on nutrition and dietetics, take part in web casting, videoconferencing and other activities to promote education and research. The Network members will be encouraged to share learning materials and develop opportunities for lifelong learning and continuing professional development. In addition regular electronic newsletters, conferences and other dissemination activities are planned.
Appropriate behavioral methods and pelvic floor training are available.19 Olderanticholinergics Tolterodine and oxybutynin are muscarinic receptor antagonists. Oxyhutynin also displays antispasmodic activity in smooth muscle. These agents are recommended for patients with overactive bladder who remain symptomatic despite nonpharmacologic therapy.20-22 The introduction of extended-release formulations has improved tolerability without substantively impairing the effectiveness of these drugs.23-27 Completion rates in long-term studies approach 70 percent with extendedrelease tolterodine, but are as low as 18 percent with immediate-release oxybutynin.28-30 On average, anticholinergic therapy reduces weekly urge-incontinence episodes by 70 percent. Dry mouth is the most common adverse event, affecting 20 to 30 percent of patients administered these agents.28-30 A Cochrane review of randomized controlled trials comparing anticholinergic drugs with placebo or no treatment in patients with overactive bladder showed that patients treated with anticholinergics were more likely to report cure or improvement in their symptoms than those receiving placebo 60 versus 45 percent; P .05, number needed to treat 7 ; .31 Maximal cystometric capacity increased 54 mL in patients receiving anticholinergics compared with those receiving placebo. Dry mouth was reported significantly more often in the active medication group 32 versus 14 percent; P .05, number needed to harm 5 however, similar numbers of patients withdrew because of adverse events. Drug therapy resulted in approximately one less episode of leakage and one less void per 48 hours compared with placebo. Because the placebo-adjusted effectiveness of these agents is marginal, the clinical impact must be weighed against the risk of adverse events. neweragents Head-to-head studies comparing the three newer agents--trospium, solifenacin, and darifenacin--with immediate-release oxybutynin and tolterodine have suggested similar effectiveness across the class.10-14, 16 Although the attributes of these newer agents in theory could improve tolerability, clinical trials comparing relevant agents to validate this are lacking Table 2 ; .10-16 and ventolin.
Note: The FDA requires on-site test devices to be accurate within 25% of the drug screen's cut-off level. The iSCREEN detected all but two of the GC MS positive specimens within + 25% of the screen's 50ng cut-off. The only GC MS positive specimens not identified as positive by the iSCREEN were close to or below the iSCREEN `s 50 ng cut-off. Specimens whose results differed between the GC MS and the iSCREEN contained the following concentration levels in ng ml: 15, 16, and 79.
The earth itself produces some energy fields that are detrimental to human health as well, commonly referred to as geopathic stress and cimetidine.
Oxybutynin for men
IOPacTM Advanced Handheld Pachymeter is a portable, pocket-sized pachymeter designed for glaucoma and potential refractive surgery patients. Based on Palm technology, the IOPac provides accurate one-touch measurement and is fast and easy to use. It also automatically corrects a patient's IOP for corneal thickness using one of five built-in reference formulas, stores up to 1000 patient exams and provides easy printing for documentation.With a lightweight, pocket size design; and color, backlit screen, the IOPac ensures effortless data evaluation in one convenient portable package, for instance, ic oxybutynin.
Oxybutynin pills
Elementary schools in 3 counties. Specific activities include forming walking fitness clubs and lifetime sports programs in 10 elementary schools. healthy role models, work with teachers to integrate nutrition lessons into the curriculum, implement Be Active's Active Steps Youth Program in target schools, and work with community agencies to hold a family health night at each target school. This group also plans to measure children's BMI and send results to parents and differin.
Oxybutynin products
Paul october he was honored for his years of leadership and service in the mma and for his outstanding contributions to organized medicine, for instance, oxybutynin chloride.
Submitted supported usc address medicine and eldepryl.
Late-Stage Pipeline continued Mechanism of action Trospium exhibits predominantly antimuscarinic effects that are not specific to any muscarinic receptor subtypes. Trospium has a quarternary ammonium group as opposed to the tertiary ammonium group of atropine ; that prevents it from crossing the blood-brain barrier into the central nervous system. Competitors Currently marketed FDA-approved treatments for overactive bladder include anticholinergics such as oxybutynin chloride Ditropan XL, Johnson & Johnson ; and tolterodine tartrate DetrolTM and Detrol LA, Pharmacia Pfizer ; . These marketed drugs are lipophilic and can cross the blood-brain barrier, which can cause central nervous system side effects. Trospium has not demonstrated an ability to cross this barrier. At therapeutic amounts, Trospium does not inhibit the specific enzymes in the Cytochrome P450 system, a drug metabolizing system that is often implicated in adverse drug-drug interactions. Trospium is excreted in the urine mostly as the parent compound and due to its low rate of dry mouth is well tolerated. In addition, Watson Pharmaceuticals has recently launched the oxybutynin patch Oxytrol Patch ; . There are also companies evaluating antimuscaranics and antispasmodics. Two developmental-stage products that stand out are solifenacin Vesicare, Yamanouchi GlaxoSmithKline ; and darifenacin Enablex, Novartis ; . GlaxoSmithKline and Yamanouchi's drug, Vesicare, and Novartis's drug, Enablex, have both received an "approvable letter" from the FDA. Both of the companies are required to submit additional information to the FDA and these drugs are not expected to reach the market until 2H 2004. Solifenacin is available as a 5mg and 10mg dose that has only been tested in Europe. The 5mg dose has an incidence of dry mouth believed to be in the high single digits, which will make it an extremely competitive drug for Trospium. In addition, the marketing power of Yamanouchi and GlaxoSmithKline will make the marketplace challenging for Indevus. The 10mg dose has a 23% incidence of dry mouth incidence and darifenacin has a comparable incidence rate to solifenacin. Assessment All compounds are antimuscarinics with varying specificities for the muscarinic receptor subtypes. All antimuscarinics appear to have similar efficacies in treating the symptoms associated with overactive bladder; however, the most predominant issue with the use of antimuscarinics is the adverse reactions, particularly dry mouth. The M3 muscarinic receptor also regulates the salivary glands; consequently, inhibition of the M3 receptor results in decreased salivary secretion and dry mouth. Thus, an antimuscarinic specific for the M3 receptor is not necessarily as desirable as a nonspecific antimuscarinic with better tolerability: this is the case with current antimuscarinics. Studies have shown that dry mouth is reported in 6980% of patients taking oxybutynin, which is more selective for the M3 receptor, compared to 30-50% of patients taking tolterodine, a nonselective antimuscarinic. In contrast, a meta-analysis of clinical trials performed with Trospium, a nonspecific antimuscarinic, reported 4.1% of patients taking Trospium developed dry mouth. Although there are no published clinical trials with darifenacin, a pre-clinical study on guinea pig detrusor muscle has shown that, although darifenacin exhibits selectivity in binding for the M3 receptor, its effect on bladder contraction and salivary glands are equivalent. Solifenacin had a fairly equivalent effect on bladder contraction and inhibiting salivary gland secretion. Market Size 17M people in the U.S. are believed to suffer from OAB and 85% of the disease population consists of women. According to a SCRIP Report, approximately 20% of the patients are treated using pharmacotherapy, with costs nearing $26B. The reason for limited patient treatment is due to the following: 1 ; evolving awareness that this condition can be treated with pharmacotherapy as many patients wear diapers; 2 ; high incidence of dry mouth. The market size is estimated to be $1.2B this year, a rise from $990M in 2002. It is expected to exceed $2B by 2008. In Europe, the overall OAB market is approximately $175-200M. In the countries that Madaus has a strong presence, the revenues are similar for Trospium versus Detrol LA and Ditropan XL. Trospium is priced lower in the market, but the revenues are on par with Detrol LA and Ditropan XL. The average wholesale price is $2.60 a day and $3.10 a day for a self-payer. In the new prescription market, 55% of all new cases are treated by primary care physicians, 28% by urologists, and 18% by obstetricians, gynecologists and other specialists. Indevus is targeting the top seven deciles of prescribing physicians. There are 6000-7000 urologists that could utilize this product and rapidly enhance its market position.
To offer result-oriented skin care products with ingredients that do not compromise personal health or our environment and are vegetarian vegan friendly and feldene.
It also helps to decrease muscle spasms of the bladder ditropan related products: oxyubtynin chloride , ditropan oxyspas , oxybutyn9n , ditropan tropan xl , ditropan xl , ox7butynin ditropan at freedompharmacy it muscle bladder.
Derrick Eaves, English teacher at Niagara College, edits an assignment. Photo by Robbie-Lyn Fawcett Eaves says he plans to still be the largest rainbow trout, and I teaching at Niagara College. hope to finally figure out how to "I also hope to finally be the grow a half decent vegetables in world record holder for catching my garden and frusemide and oxybutynin, for instance, oxybutynin transdermal system.
Oxybutynin canada
TABLE 10 Summary of comparisons, outcomes and results from effectiveness studies cont'd ; Outcome Data RR, 95% CI dichotomous outcomes ; Mean difference, 95% CI continuous outcomes ; RR 1.25 95% CI 0.64 to 2.23 RR 0.87 95% CI 0.5 to 1.59 RR 1.09 95% CI 0.55 to 2.07.
Speaker: Lindsey A. Kerr, MD, Associate Professor of Urology and Director, Pelvic Floor Disorder Center, University of Utah Health Sciences Center, Salt Lake City, Utah. Preliminary data indicate that a majority of patients report high levels of satisfaction with transdermal oxybutynin Oxytrol Transdermal System, Watson Pharma, Inc. ; TDS ; and prefer the patch to other oral therapies for overactive bladder OAB ; . Although clinical trials of oxybutynin TDS for OAB have demonstrated the efficacy and safety of this approach, as well as a low incidence of anticholinergic effects that are commonly seen with oral medications for OAB, few data are available in terms of patient satisfaction with this transdermal treatment. The Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybu5ynin MATRIX ; study was conducted to assess safety, health-related quality of life, and other patient-reported outcomes in a large patient population. This is an ongoing, open-label, randomized, multicenter prospective six-month study in community-dwelling adults with OAB. To date, 2, 878 patients 87% female ; are receiving oxybutynin TDS 3.9 mg day. Most of the participants 1, 632 patients ; have a history of having received OAB pharmacotherapy, and 32% have taken multiple ineffective medications. For this initial analysis, 1, 609 patients participated in telephone interviews, answering questions regarding their experience with the patch after one month of treatment. Overall, 69.6% of the women in the group were "very satisfied" or "satisfied" with oxybutynin TDS. Patients reported high levels of satisfaction with the product's effectiveness, tolerability, and ease of application. Approximately 75% of patients considered oxybutynin TDS "very convenient" or "convenient, " and more than 65% of patients said that they were not bothered by "aware of" ; the patch during daily activities. Of patients who were "aware of" the patch, 71% said that it "rarely" or "never" affected their daily activities. For patients who had received previous OAB therapy, 63.4% stated that oxybutynin TDS offered benefits over their previous treatments. As in the total study group, these patients were more satisfied with the ease of application, effectiveness, and tolerability compared with earlier therapies. I and keflex.
Unity Healthcare, a physician owned and managed multi-specialty group, currently seeks a BE BC Gastroenterologist. Interested candidates should be trained proficient in ERCP.
Bcpkn~m.Hl$mxynaFhthat~Gnnuf~.Sg * ~Bmid.Specmtm" rndrclmintic kvamisole, Thiambcndazole etc ; . Niclosamide Tabs - 900 mg Pipcrazinc Adipatc Tabs - 300 mg . Tctnchlorocthylcne.
Medications Cheap Drugs
At one time a popular street drug, in a sufficient dose, barbiturates produce a stuporous, dazed, half-conscious sensation— similar to being drunk— often accompanied by irritability and belligerence.
SOMNOTE 500 MG SOFTGEL SOMNOTE 500 MG SOFTGEL OXYCODONE W APAP 5 500 CAP OXYCODONE W APAP 5 500 CAP OXYCODONE W APAP 5 325 TAB OXYCODONE W APAP 5 325 TAB MEPERIDINE 100 MG TABLET MEPERIDINE 100 MG TABLET MEPERIDINE 50 MG TABLET MEPERIDINE 50 MG TABLET PEMOLINE 37.5 MG TABLET PEMOLINE 75 MG TABLET OXYCODONE 5 MG TABLET OXYCODONE 5 MG TABLET BETAXOLOL 10 MG TABLET BETAXOLOL 20 MG TABLET PEMOLINE 37.5 MG TABLET CHEW OXYCODONE 5 MG CAPSULE PEMOLINE 18.75 MG TABLET PENTAZOCINE NALOXONE TABLET PENTAZOCINE NALOXONE TABLET PENTAZOCINE ACETAMIN TABLET OXYCODONE HCL 15 MG TABLET OXYCODONE HCL 30 MG TABLET MIRTAZAPINE 15 MG TABLET MIRTAZAPINE 30 MG TABLET MIRTAZAPINE 45 MG TABLET QUINARETIC 10-12.5 MG TABLET QUINARETIC 10-12.5 MG TABLET QUINARETIC 20-12.5 MG TABLET QUINARETIC 20-12.5 MG TABLET QUINARETIC 20-25 MG TABLET QUINARETIC 20-25 MG TABLET MIRTAZAPINE 15 MG RPD DISLV TB MIRTAZAPINE 30 MG RPD DISLV TB MIRTAZAPINE 45 MG RPD DISLV TB OCUSULF-10 EYE DROPS OCUSULF-10 EYE DROPS OCUSULF-10 EYE DROPS PILOCARPINE 0.5% EYE DROPS PILOPTIC-1 EYE DROPS PILOPTIC-2 EYE DROPS PILOPTIC-3 EYE DROPS PILOPTIC-4 EYE DROPS PILOPTIC-6 EYE DROPS PHOSLO 667 MG TABLET ACYCLOVIR 400 MG TABLET ACYCLOVIR 800 MG TABLET VERAPAMIL 80 MG TABLET VERAPAMIL 80 MG TABLET VERAPAMIL 80 MG TABLET VERAPAMIL 120 MG TABLET VERAPAMIL 120 MG TABLET VERAPAMIL 120 MG TABLET DILACOR XR 120 MG CAPSULE SA DILACOR XR 180 MG CAPSULE SA DILACOR XR 180 MG CAPSULE SA DILACOR XR 240 MG CAPSULE SA DILACOR XR 240 MG CAPSULE SA NORCO 10 325 TABLET NORCO 10 325 TABLET MAXIDONE 10 750 MG TABLET NORCO 7.5 325 TABLET DILTIAZEM 90 MG TABLET DILTIAZEM 120 MG TABLET OXYBUTYNIN 5 MG TABLET OXYBUTYNIN 5 MG TABLET NORCO 5 325 TABLET OXYTROL 3.9 MG 24HR PATCH FIORINAL W CODEINE #3 CAPSULE FIORICET W CODEINE CAPSULE REPREXAIN 5-200 MG TABLET DICLOFENAC SOD 75 MG TAB EC DICLOFENAC SOD 75 MG TAB EC CIPROFLOXACIN HCL 250 MG TAB CIPROFLOXACIN HCL 500 MG TAB CIPROFLOXACIN HCL 750 MG TAB CIPROFLOXACIN HCL 750 MG TAB PIROXICAM 10 MG CAPSULE PIROXICAM 20 MG CAPSULE PIROXICAM 20 MG CAPSULE CORT-BIOTIC EAR SUSPENSION FP ALLERGY RELIEF 10 MG TABLET FP ALLERGY RELIEF 5 MG 5 ALLERGY RELIEF 10 MG TABLET FP IBUPROFEN JR STR 100 MG TAB FP CHILD'S IBUPROFEN SUSP FP LORATADINE 10 MG TABLET FP LORATADINE 10 MG TABLET FP ALLERGY-CONGEST RELIEF TAB FP INFANT'S IBUPROFEN ORAL SUS FP CHILD'S IBUPROFEN SUSP FP IBUPROFEN 200 MG TABLET.
Different from urge incontinence see s ; -oxybutynin above ; , stress incontinence is the involuntary escape of a small amount of urine when a person coughs, laughs, or lifts heavy objects and prednisolone.
Oxybutynin drug interactions
Medications should never be prescribed without a patient medical history and patients should always inquire with the prescribing physician before taking any new medications, including over the counter medications and herbal remedies!
What should i watch for while taking oxybutynin.
What is Oxybutynin
The measured cell constant should be consistent with the given value within 5z. If it is not consistent, coat the electrodes with platinum black again, or replace the cell with a new one. 2 ; Suitability Test for the Apparatus Using an appropriate KCl standard solution according to the expected conductivity of the sample solution, perform the suitability test for the apparatus. Rinse the conductivity cell several times with distilled water, and rinse again 2 3 times with the selected standard solution. Fill the standard solution in the measuring vessel. After con rming that the temperature of the measuring system is maintained at 20 0.19 measure the conductivity of the standard solution. C, When this measuring procedure is repeated several times, the average conductivity should be consistent with an indicated value in Table 1 within 5z. Further, the relative standard deviation should be less than 2z. 3 ; Measurement After con rmation of the suitability of the apparatus, perform the conductivity measurement for the sample solution. Unless otherwise speci ed, the preparation method for sample solution should be as speci ed in the respective monograph. Rinse the conductivity cell several times with distilled water, and rinse again 2 3 times with sample solution. Immerse the cell in the sample solution placed in a measuring vessel. If necessary, agitate gently the sample solution. After con rming that the temperature of the sample solution is C maintained at 20 0.19 or at the temperature speci ed in the monograph, measure the resistance RT MQ ; or conductance GT mS ; of the sample solution, and calculate the conductivity kT by using the following equation.
| Oxybutynin sideManaged Care; Bausch & Lomb, Inc.: Retisert, ReNu, Nutraceuticals, Pure Vision Toric; First Horizon: Nitrolingual, Sular; Roche Laboratories: Kytril, Pegasys; Sepracor: Estorra, Xopenex; Serono: Gonal F Pen, reproductive portfolio; Tempur-Pedic: Tempur-Pedic Beds. Torre Lazur Chicago -- Healthcare accounts: Abbott Laboratories: Humira U.S. & Global ; , Kaletra U.S. & Global ; , Depakote. Torre Lazur West -- Healthcare accounts: Avanir Pharmaceuticals: AVP-932; CancerVax: Canvaxin; CV Therapeutics, Inc.: Ranexa; Gilead Sciences: Emtriva, Viread. Accounts gained 24 ; : Torre Lazur McCann -- 11 accounts gained: Bristol-Myers Squibb Sanofi: Plavix; Dermik Laboratories, Inc.: Sculptra; GlaxoSmithKline Consumer Healthcare: Aclovate; Ortho-McNeil Pharmaceutical, Inc.: Axert; Ethicon Endo-Surgery, GI Division: Harmonic Scalpel; Adams Respiratory: Sinu-mentin; Gilead: Emtriva, Viread; Biovail: Cardizem LA, Teveten, Teveten HCT. Torre Lazur Communications -- 9 accounts gained: Aspect Medical: BIZ; Aventis: Lantus Managed Care; Bausch & Lomb, Inc.: Nutraceuticals, Pure Vision Toric; First Horizon: Nitrolingual, Sular; Serono: Gonal F Pen, reproductive portfolio; Tempur-Pedic: Tempur-Pedic Beds. Torre Lazur Chicago -- 1 account gained: Abbott Laboratories: Depakote. Torre Lazur West -- 3 accounts gained: Gilead Sciences: Emtriva, Viread; CancerVax: Canvaxin Accounts lost 6 ; : Torre Lazur McCann -- 1 account lost: Pharmacia: Zyvox. Torre Lazur Communications -- 2 accounts lost: Aventis: Amaryl; Genzyme: Renagel. Torre Lazur West -- 3 accounts Lost: Medicis Pharmaceutical Corporation: Dynacin; SkinMedica, Inc.: TNS Recovery, EpiQuin Micro. Services: Audiovisual production, medical education, publication planning, live meeting planning and management, exhibitions, publishing, interactive, managed care marketing, multicultural healthcare marketing, relationship marketing, public relations, new media, contract research organization. Offices: Torre Lazur McCann, Parsippany, N.J.; Torre Lazur Communications, East Hanover, N.J.; Torre Lazur Chicago, Chicago, Ill.; Torre Lazur McCann West, San Diego, Calif.; AdairGreene Torre Lazur Atlanta, Atlanta, Ga. Divisions: Medical Communications: Complete Medical Communications, Horsham, Pa.; Scientific Frontiers, Newtown, Pa.; Vizion Medical Communications, San Diego and Los Angeles, Calif.; Torre Lazur Managed Markets, Parsippany, N.J.; HealthLink, Parsippany, N.J.; CRO: Target Research Associates, New Providence, N.J.; Torre Lazur Consumer Communications, Parsippany, N.J. FEATURED WORK Product: Oxytrol Client: Watson Pharmaceutical Creative account team: Account team: Channia Holt, Mark Goodson, Jen Tindal, Darlene Dobry; creative team: Peggy O'Connor, Jill Lesiak, Jason Coleman, Scott Watson. Media team: Kathy Sullivan. Why this ad is special: The Comfort Zone Oxytrol for Overactive Bladder OAB ; . Oxytrol is a novel transdermal "patch" for OAB. We leveraged the established power of oxybutynin in its new transdermal form and presented the unique benefit of Oxytrol: powerful efficacy with low anticholinergic side effects. The creative campaign invited physicians and patients to Get Inside the Comfort Zone. The result: 80% of urologists now rank Oxytrol as "1st choice" due to its improved side effect profile.
© 2005-2007 Generic.fizwig.com, Inc. All rights reserved.
|
|
